Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 3/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.53 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22630849 | 1.00 | PLA2G10 (0.53) | PLA2G10PLA2G2APLA2G5L3MBTL1TRPM8 | |
| SCHEMBL17761208 | 1.00 | PLA2G10 (0.53) | PLA2G10PLA2G2APLA2G5L3MBTL1TRPM8 | |
| SCHEMBL12895271 | 0.84 | L3MBTL1 (0.68) | L3MBTL1TRPM8GPR139CTSAEPHX1 | |
| SCHEMBL22643601 | 0.84 | L3MBTL1 (0.49) | PLA2G10PLA2G2APLA2G5L3MBTL1TRPM8 | |
| SCHEMBL12835623 | 0.82 | EPHX1 (0.50) | PLA2G10PLA2G2APLA2G5EPHX1MMP12 | |
| SCHEMBL12895100 | 0.82 | EPHX1 (0.50) | PLA2G10PLA2G2APLA2G5EPHX1MMP12 | |
| SCHEMBL12836521 | 0.82 | EPHX1 (0.50) | PLA2G10PLA2G2APLA2G5EPHX1MMP12 | |
| SCHEMBL27649238 | 0.81 | TRPM8 (0.49) | PLA2G10PLA2G2APLA2G5L3MBTL1TRPM8 | |
| SCHEMBL11531884 | 0.80 | PTGS1 (0.61) | L3MBTL1 | |
| SCHEMBL21303055 | 0.79 | HDAC4 (0.45) | PLA2G10PLA2G2APLA2G5GPR139HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3755684-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2020-12-30 | — | — | EP | disclosed |
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019161877-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-29 | — | — | WO | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9206143-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | PLA2G10 3287/4885PLA2G2A 3213/4885PLA2G5 4153/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | PLA2G10 2878/4885PLA2G2A 3069/4885PLA2G5 3887/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | PLA2G10 3287/4885PLA2G2A 3213/4885PLA2G5 4153/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | PLA2G10 3534/4885PLA2G2A 3330/4885PLA2G5 4305/4885 |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | CHRNA10, CHRNA6, GAP43 | PLA2G10 3363/4885PLA2G2A 3105/4885PLA2G5 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.